Mark Pomeranz - Motus GI NonIndependent CEO
| MOTSDelisted Stock | USD 0.08 0.01 15.56% |
CEO
Mr. Mark Pomeranz appointed as President, Chief Operating Officer, Director of the Company., effective October 1, 2018. He was Chief Executive Officer and Director of the Company. Mr. Pomeranz was Chief Executive Officer of Opco since 2014 and has served as our CEO since the Share Exchange Transaction. Prior to joining Opco, from 2007 to 2014, Mr. Pomeranz was the founding CEO of Svelte Medical Systems, a startup company that is currently commercializing a unique drug eluting stent platform in the EU. From 1998 to 2007, Mr. Pomeranz served as Vice President at Cordis, a Johnson Johnson Company, where his responsibilities included developing new technologies, exploring new market opportunities and leading major restructuring efforts to create crossfunctional global commercialization teams. Prior to that, Mr. Pomeranz held a number of senior leadership roles, including positions at Cardiac Pathways Corporationrationrations from 1991 to 1998, and Cardiovascular Imaging Systems from 1989 to 1991, both of which were acquired by Boston Scientific Corporationrationration. Mr. Pomeranz earned a M.Sc. in biomedical engineering from the University of Miami. since 2018.
| Age | 62 |
| Tenure | 6 years |
| Phone | 954 541 8000 |
| Web | https://www.motusgi.com |
Motus GI Management Efficiency
The company has return on total asset (ROA) of (0.5985) % which means that it has lost $0.5985 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.5434) %, meaning that it created substantial loss on money invested by shareholders. Motus GI's management efficiency ratios could be used to measure how well Motus GI manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 6 records | CEO Age | ||
| Joseph Yanchik | Aileron Therapeutics | 51 | |
| Francis Amato | Electrocore LLC | N/A | |
| William Densel | Check Cap | 47 | |
| David Domzalski | Vyne Therapeutics | 57 | |
| John Longenecker | Aileron Therapeutics | 57 | |
| Alex Ovadia | Check Cap | 62 | |
Management Performance
| Return On Equity | -4.54 | ||||
| Return On Asset | -0.6 |
Motus GI Holdings Leadership Team
Elected by the shareholders, the Motus GI's board of directors comprises two types of representatives: Motus GI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Motus. The board's role is to monitor Motus GI's management team and ensure that shareholders' interests are well served. Motus GI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Motus GI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Pomeranz, NonIndependent CEO | ||
| Jenene Thomas, IR Contact Officer | ||
| Timothy Moran, CEO, Director | ||
| Andrew MBA, Chief Officer | ||
| Gary Pruden, Independent Director | ||
| Scott Aldrich, VP Strategy | ||
| Andrew Taylor, CFO | ||
| Ravit Ram, CFO Operations | ||
| Gary Jacobs, Independent Director | ||
| Elad Amor, Chief Officer | ||
| David Hochman, Independent Chairman of the Board | ||
| Shervin Korangy, Independent Director | ||
| Darren Sherman, Independent Director | ||
| Samuel Nussbaum, Independent Director |
Motus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Motus GI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.54 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (62.33) % | ||||
| Current Valuation | (1.62 M) | ||||
| Shares Outstanding | 5.21 M | ||||
| Shares Owned By Insiders | 1.11 % | ||||
| Shares Owned By Institutions | 4.70 % | ||||
| Number Of Shares Shorted | 23.24 K | ||||
| Price To Earning | (1.89) X | ||||
| Price To Book | 0.51 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Motus GI Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Motus Stock
If you are still planning to invest in Motus GI Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Motus GI's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stocks Directory Find actively traded stocks across global markets |